Arcus Biosciences (RCUS) EBT (2017 - 2025)
Historic EBT for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$135.0 million.
- Arcus Biosciences' EBT fell 4673.91% to -$135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$340.0 million, marking a year-over-year decrease of 2639.41%. This contributed to the annual value of -$282.0 million for FY2024, which is 631.23% up from last year.
- Arcus Biosciences' EBT amounted to -$135.0 million in Q3 2025, which was down 4673.91% from -$112.0 million recorded in Q1 2025.
- Arcus Biosciences' EBT's 5-year high stood at $281.5 million during Q4 2021, with a 5-year trough of -$135.0 million in Q3 2025.
- In the last 5 years, Arcus Biosciences' EBT had a median value of -$75.0 million in 2021 and averaged -$57.8 million.
- Within the past 5 years, the most significant YoY rise in Arcus Biosciences' EBT was 64147.13% (2021), while the steepest drop was 437963.78% (2021).
- Quarter analysis of 5 years shows Arcus Biosciences' EBT stood at $281.5 million in 2021, then plummeted by 123.8% to -$67.0 million in 2022, then dropped by 19.4% to -$80.0 million in 2023, then decreased by 16.25% to -$93.0 million in 2024, then crashed by 45.16% to -$135.0 million in 2025.
- Its last three reported values are -$135.0 million in Q3 2025, -$112.0 million for Q1 2025, and -$93.0 million during Q4 2024.